Current Report Filing (8-k)
30 September 2022 - 6:16AM
Edgar (US Regulatory)
0000012239
false
0000012239
2022-09-23
2022-09-23
iso4217:USD
xbrli:shares
iso4217:USD
xbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d)
of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
September 23, 2022
AIKIDO PHARMA INC.
(Exact name of registrant as specified in its charter)
Delaware |
|
000-05576 |
|
52-0849320 |
(State or other jurisdiction
of incorporation) |
|
(Commission
File Number) |
|
(IRS Employer
Identification No.) |
One Rockefeller Plaza, 11th Floor, New York, NY |
|
10020 |
(Address of principal executive offices) |
|
(Zip Code) |
Registrant’s telephone number, including area
code: (703) 993-9325
N/A
(Former name or former address, if changed since last
report.)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
☐ |
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
☐ |
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
☐ |
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
☐ |
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13a-4(c)) |
Title of each class |
Trading Symbol(s) |
Name of each exchange on which registered |
Common Stock, $0.0001 par value |
AIKI |
The Nasdaq Capital Market LLC |
Indicate by check mark whether the registrant is an emerging growth
company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange
Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark
if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐
| Item 1.01. | Entry Into a Material Definitive Agreement. |
On September 23, 2022, Dominari Financial, Inc. (“Dominari”),
a wholly owned subsidiary of AIkido Pharma, Inc, (the “Company”) entered into a Lease Agreement (the “Lease”)
with Trump Tower Commercial LLC, a New York limited liability company.
Pursuant to the Lease, Dominari will rent a portion
of a floor at 725 Fifth Avenue, New York, New York (the “Premises”). Dominari plans to use the Premises to run its day-to-day
operations.
The initial term of the Lease is seven (7) years commencing
on the date that possession of the Premises is delivered to Dominari.
Pursuant to the Lease, Dominari will pay rent equal
to forty-nine thousand three hundred and sixty-eight dollars per month. Effective for the sixth and seventh years of the Lease, the rent
shall increase to fifty-one thousand eight hundred and sixty-eight dollars per month.
The foregoing is a summary of the terms of the Lease,
a copy of the Lease will be filed with the Company’s next Quarterly Report on Form 10-Q.
SIGNATURES
Pursuant to the requirements of the Securities Exchange
Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Dated: September 29, 2022 |
AIKIDO PHARMA INC. |
|
|
|
By: |
/s/ Anthony Hayes |
|
Name: |
Anthony Hayes |
|
Title: |
Chief Executive Officer |
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Mar 2024 to Apr 2024
Alkido Pharma (NASDAQ:AIKI)
Historical Stock Chart
From Apr 2023 to Apr 2024